RxDoctor Payments Data

Cristian Romero, MD

Internal Medicine · Cypress, TXNPI 1356504484

Payments from drug & device makers

$4,322in general payments, 2019–2025

Across 266 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$770
  • Lilly USA, LLC$534
  • Amgen$390
  • AstraZeneca$375
  • Bayer$284
  • Boehringer Ingelheim$228
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$4,316100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,322 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$69,716
Medicare patients
142
Services billed
964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide145$173,995
MounjaroTirzepatide118$151,368
JardianceEmpagliflozin35$53,461
FarxigaDapagliflozin Propanediol42$44,425
Synjardy XrEmpagliflozin/Metformin Hcl40$40,390
Xigduo XrDapaglifloz Propaned/Metformin28$35,701
LinzessLinaclotide23$28,612
RybelsusSemaglutide17$25,005
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog25$18,792
EliquisApixaban13$15,433
Repatha SyringeEvolocumab21$12,340
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$7,525
Atorvastatin Calcium272$2,614
Rosuvastatin Calcium149$2,100
Gabapentin139$1,805

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$770$199,000162 claims
Lilly USA, LLCMounjaro$534$151,368118 claims
Boehringer IngelheimJardiance, Synjardy Xr$228$93,85175 claims
AstraZenecaFarxiga$375$44,42542 claims
AbbVieLinzess, Synthroid$141$29,58050 claims
PfizerEliquis, Paxlovid$190$16,86231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Cypress

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →